4D Molecular Therapeutics Inc (NASDAQ: FDMT) on Monday, plunged -6.81% from the previous trading day, before settling in for the closing price of $6.31. Within the past 52 weeks, FDMT’s price has moved between $5.58 and $36.25.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 111.29% over the last five years. The company achieved an average annual earnings per share of -13.00%. With a float of $38.13 million, this company’s outstanding shares have now reached $52.00 million.
The firm has a total of 147 workers. Let’s measure their productivity. In terms of profitability, gross margin is -43747.06%, operating margin of -990447.06%, and the pretax margin is -844000.0%.
4D Molecular Therapeutics Inc (FDMT) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of 4D Molecular Therapeutics Inc is 17.53%, while institutional ownership is 99.00%. The most recent insider transaction that took place on Sep 16 ’24, was worth 8,165. In this transaction Chief Legal Officer of this company sold 500 shares at a rate of $16.33, taking the stock ownership to the 6,781 shares. Before that another transaction happened on Aug 19 ’24, when Company’s Chief Legal Officer sold 500 for $15.00, making the entire transaction worth $7,500. This insider now owns 6,781 shares in total.
4D Molecular Therapeutics Inc (FDMT) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.82 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -13.00% per share during the next fiscal year.
4D Molecular Therapeutics Inc (NASDAQ: FDMT) Trading Performance Indicators
4D Molecular Therapeutics Inc (FDMT) is currently performing well based on its current performance indicators. A quick ratio of 17.33 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 13.49.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.73, a number that is poised to hit -0.84 in the next quarter and is forecasted to reach -3.56 in one year’s time.
Technical Analysis of 4D Molecular Therapeutics Inc (FDMT)
Analysing the last 5-days average volume posted by the [4D Molecular Therapeutics Inc, FDMT], we can find that recorded value of 1.96 million was better than the volume posted last year of 0.91 million. As of the previous 9 days, the stock’s Stochastic %D was 23.30%. Additionally, its Average True Range was 0.50.
During the past 100 days, 4D Molecular Therapeutics Inc’s (FDMT) raw stochastic average was set at 2.54%, which indicates a significant decrease from 15.00% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 71.86% in the past 14 days, which was higher than the 66.30% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $7.75, while its 200-day Moving Average is $17.82. Now, the first resistance to watch is $6.22. This is followed by the second major resistance level at $6.56. The third major resistance level sits at $6.79. If the price goes on to break the first support level at $5.66, it is likely to go to the next support level at $5.43. Should the price break the second support level, the third support level stands at $5.09.
4D Molecular Therapeutics Inc (NASDAQ: FDMT) Key Stats
Market capitalization of the company is 296.75 million based on 46,228K outstanding shares. Right now, sales total 20,720 K and income totals -100,840 K. The company made 10 K in profit during its latest quarter, and -34,950 K in sales during its previous quarter.
